Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics will present three abstracts on its investigational intravenous Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, highlighting potential improvements over existing mTOR inhibitors for metastatic breast cancer treatment.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that three abstracts featuring its investigational intravenous Deciparticle everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9-12 in San Antonio, Texas. The acceptance of multiple abstracts underscores the scientific community's interest in this novel formulation designed to address limitations of current mTOR inhibitors in breast cancer treatment.
Developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, Sapu003 represents a significant advancement in drug delivery technology. The intravenous formulation aims to overcome the poor bioavailability and restricted tumor penetration associated with oral mTOR inhibitors like Afinitor. This technological improvement could potentially enhance treatment efficacy for patients with HR⁺/HER2⁻ metastatic breast cancer, a population with ongoing therapeutic needs.
The three accepted abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial. This comprehensive presentation package provides validation for the scientific approach behind Deciparticle technology and demonstrates the compound's progression through clinical development. The symposium presentation will offer oncology researchers and clinicians their first detailed look at the data supporting this innovative therapeutic approach.
For investors and stakeholders seeking additional information, the company maintains its newsroom at https://ibn.fm/OTLC where updates on development progress are regularly posted. The full press release containing detailed information about the abstract acceptances is available at https://ibn.fm/Ut6V8 for those interested in the complete announcement.
The timing of these presentations coincides with growing interest in improved formulations of existing cancer therapeutics. By addressing the pharmacokinetic limitations of oral everolimus, Oncotelic's approach could potentially expand treatment options for breast cancer patients who may benefit from mTOR inhibition but struggle with current formulation limitations. The data presentation at one of oncology's premier conferences represents a significant milestone in the compound's development pathway.